| Project/Area Number |
26861343
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Tokai University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2015: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | HIF-1 / 卵巣明細胞腺癌 / HDAC7 / シリビニン / Vorinostat / HIF-1活性化阻害剤 / HDAC |
|---|
| Outline of Final Research Achievements |
Histone Deacetylase (HDAC) is an enzyme deacetylating the histone which is a main constitution factor in chromatin structure and play an important role in genetic transcription control. HDAC is involved in intracellular signal transduction and the control of the cell cycle and in late years attracts attention as target molecule of the cancer therapy.In this study, focusing on HDAC7, we analyzed their immunohistochemical expression in ovarian cancer and assessed their mRNAs expression in cultured ovarian cancer cell lines. HDAC inhibitor (HDI)-induced changes in the expression of mRNAs for HDAC7, HIF-1α and VEGF were also attempted to assess the potential anti-cancer effect of HDI.
As a result, it was shown that the inhibitory effect of HDI on HDAC7 and HIF-1 varies among cell lines. We suppose that the response to HDI may vary greatly among patients with ovarian cancer and that the ovarian cancer with high expression of HDAC7 may be a suitable candidate for HDI treatment.
|
